GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated May 1, 2024, serves as a notification to the market in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R. The report details the company's issued share capital and total voting rights as of April 30, 2024.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure and voting rights.
Material Changes
The filing does not disclose material changes in financial performance or operations compared to prior periods. It provides a static snapshot of share capital as of the reporting date.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. Its sole purpose is to inform shareholders of the denominator for calculating notification thresholds under FCA rules.
Key Facts for Investors
- Issued Share Capital: As of April 30, 2024, GSK Plc had 4,314,095,203 Ordinary Shares of 31 1/4 pence each.
- Treasury Shares: 169,171,155 Ordinary Shares were held in Treasury.
- Total Voting Rights: The total number of voting rights is 4,144,924,048.
- Regulatory Use: This voting rights figure is the required denominator for shareholders to determine if they must notify the company of their interest or changes thereto under FCA rules.
- Contact: Notifications should be sent to company.secretary@gsk.com.